Gene Therapy CRMA-1001 Silences Hepatitis B Viral DNA
The experimental gene therapy CRMA-1001 offers a novel approach to treating hepatitis B by silencing the virus's DNA rather than targeting the virus directly. This is significant because current treatments rarely eliminate the viral DNA, allowing the virus to rebound. CRMA-1001's ability to mute viral DNA could prevent hepatitis B recurrence and improve long-term outcomes.
Hindu Science·




